newsfilter
← Latest News
GlobeNewswire·

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at